Post_template - Page 9 of 10

OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics

On April 1, 2021, OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics, joining our team in Vienna, Austria. Friedmund will provide valuable support in manufacturing, analytics, and quality control efforts.

BIO-Europe Spring Digital Event, March 22–25, 2021

Meet our CEO, Randolf Kerschbaumer and CSO, Michael Thiele at the digital BIO-Europe Spring to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

OncoOne warmly welcomed Alejandro Puchol Tarazona, PhD as our new Scientist

On March 1, 2021, OncoOne warmly welcomed Alejandro Puchol Tarazona, PhD to our Biotechnology Group as our new Scientist. Alejandro will contribute his expertise to support protein engineering activities and protein production.

OncoOne Establishes Scientific Advisory Board to Support OxMIF-targeted Anti-Cancer Drug Development Programs.

PDF Klosterneuburg, Austria – September 3, 2020 – OncoOne, today announced the establishment of a Scientific Advisory Board to provide strategic, scientific and preclinical and clinical research guidance for OncoOne’s drug development programs based on targeting the oxidized macrophage migration inhibitory factor (oxMIF). OxMIF is an

OncoOne is pleased to welcome Maria Reitzinger as our new Management Assistant.

On June 1, 2020, OncoOne warmly welcomed Maria Reitzinger to our team as our new management assistant. Maria will play a vital role in supporting our CEO with organizational and administrative tasks.

OncoOne opens its laboratory and office at the Vienna BioCenter

As of April 1, 2020, OncoOne has relocated its laboratory and office operations to the Vienna BioCenter. While our primary headquarters remains in Klosterneuburg, this move signifies an expansion of our presence within the vibrant scientific community at the Vienna BioCenter.

OncoOne Launches with EUR 13 Million Series A to Develop Multiple Drug Modalities for Unexplored Target.

PDF Klosterneuburg, Austria – March 18, 2020 – OncoOne, today announced the close of a EUR 13 million Series A financing round, marking its industry debut. OncoOne will develop several drug modalities to target oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory

OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics

BIO-Europe Spring Digital Event, March 22–25, 2021

OncoOne warmly welcomed Alejandro Puchol Tarazona, PhD as our new Scientist

OncoOne Establishes Scientific Advisory Board to Support OxMIF-targeted Anti-Cancer Drug Development Programs.

OncoOne is pleased to welcome Maria Reitzinger as our new Management Assistant.

OncoOne opens its laboratory and office at the Vienna BioCenter

OncoOne Launches with EUR 13 Million Series A to Develop Multiple Drug Modalities for Unexplored Target.

BIO-Europe November 11–13, 2019, Hamburg, DE

OncoOne is delighted to welcome Irina Mirkina, PhD as our new Senior Scientist.

OncoOne is pleased to introduce our first employee, Gregor Rossmüller, BSc.

OncoOne

Contact us

Email us

Follow us